AGIOS PHARMACEUTICALS, INC. 8-K

What Happened Agios Pharmaceuticals, Inc. announced its financial results for the quarter and full year ended December 31, 2025 via a press release issued February 12, 2026. The company filed a Current Report on Form 8-K (Item 2.02) to furnish that press release; the release is included as Exhibit 99.1 to the 8-K. The Form 8-K was signed by CEO Brian Goff.

Key Details

• Press release announcing quarterly and full‑year 2025 results issued February 12, 2026 and furnished as Exhibit 99.1 to the Form 8‑K.
• Results cover the quarter and year ended December 31, 2025 (Q4 2025 and FY 2025).
• The information furnished (including Exhibit 99.1) is not being “filed” under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
• Form 8‑K signed by Brian Goff, Chief Executive Officer.

Why It Matters This filing notifies investors that Agios has publicly released its latest quarterly and annual financial results and business highlights. Investors should review the furnished press release (Exhibit 99.1) for the company’s reported revenue, earnings, guidance, and operational updates for Q4/FY 2025. Because the release is furnished rather than “filed,” the company notes limited legal liability under Section 18 of the Exchange Act.